Detailed analysis of IFNg response upon activation permits efficient isolation of cytomegalovirus-specific CD8+ T cells for adoptive immunotherapy

Journal of Immunotherapy

Volumn 32, Issue 5, 2009, Pages 513-523

  Zandvliet, Maarten L ^a   Falkenburg, J H Frederik ^a   Jedema, Inge ^a   Willemze, Roel ^a   Guchelaar, Henk Jan ^a   Meij, Pauline ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Adoptive immunotherapy; CD8+ T cell; CMV reactivation; IFNg response

Indexed keywords

GAMMA INTERFERON; T LYMPHOCYTE RECEPTOR;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELL ISOLATION; CELL KINETICS; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOMEGALOVIRUS; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; INFECTION PREVENTION; LYMPHOCYTE ACTIVATION; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION;

CD8-POSITIVE T-LYMPHOCYTES; CELL SEPARATION; CELLS, CULTURED; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DOWN-REGULATION; FLOW CYTOMETRY; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERFERON-GAMMA; LYMPHOCYTE ACTIVATION; PEPTIDE FRAGMENTS; PHOSPHOPROTEINS; RECEPTORS, ANTIGEN, T-CELL; STEM CELL TRANSPLANTATION; T-CELL ANTIGEN RECEPTOR SPECIFICITY; VACCINATION; VIRAL MATRIX PROTEINS; VIRULENCE;

EID: 67651146453     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3181a2712c     Document Type: Article

References (51)

1. Gandhi MK, Wills MR, Sissons JG, et al. Human cytomegalovirus-specific immunity following haemopoietic stem cell transplantation. Blood Rev. 2003;17:259-264.
2. Gandhi MK, Khanna R. Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. Lancet Infect Dis. 2004;4:725-738.
3. Cwynarski K, Ainsworth J, Cobbold M, et al. Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation. Blood. 2001;97:1232-1240.
4. Hebart H, Daginik S, Stevanovic S, et al. Sensitive detection of human cytomegalovirus peptide-specific cytotoxic T-lymphocyte responses by interferon-gamma-enzyme-linked immunospot assay and flow cytometry in healthy individuals and in patients after allogeneic stem cell transplantation. Blood. 2002;99:3830-3837.
5. Avetisyan G, Larsson K, Aschan J, et al. Impact on the cytomegalovirus (CMV) viral load by CMV-specific T-cell immunity in recipients of allogeneic stem cell transplantation. Bone Marrow Transplant. 2006;38:687-692.
6. + T lymphocytes in T-cell-depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection. Blood. 2001;98:1358-1364.
7. Lacey SF, Diamond DJ, Zaia JA. Assessment of cellular immunity to human cytomegalovirus in recipients of allogeneic stem cell transplants. Biol Blood Marrow Transplant. 2004;10: 433-447.
8. + T-cell immune recovery after allogeneic stem cell transplantation. Bone Marrow Transplant. 2007;39:293-299.
9. Chakrabarti S, Mackinnon S, Chopra R, et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood. 2002;99:4357-4363.
10. Brown JM. Exogenous administration of immunomodulatory therapies in hematopoietic cell transplantation: an infectious diseases perspective. Curr Opin Infect Dis. 2005;18:352-358.
11. Landolfo S, Gariglio M, Gribaudo G, et al. The human cytomegalovirus. Pharmacol Ther. 2003;98:269-297.
12. Baldanti F, Lurain N, Gerna G. Clinical and biologic aspects of human cytomegalovirus resistance to antiviral drugs. Hum Immunol. 2004;65:403-409.
13. Boeckh M, Leisenring W, Riddell SR, et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood. 2003;101:407-414.
14. Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med. 1995;333:1038-1044.
15. Einsele H, Roosnek E, Rufer N, et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood. 2002;99:3916-3922.
16. Peggs KS, Verfuerth S, Pizzey A, et al. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet. 2003;362:1375-1377.
17. Cobbold M, Khan N, Pourgheysari B, et al. Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J Exp Med. 2005;202:379-386.
18. Perruccio K, Tosti A, Burchielli E, et al. Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation. Blood. 2005;106: 4397-4406.
19. Leen AM, Myers GD, Sili U, et al. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med. 2006;12:1160-1166.
20. Mackinnon S, Thomson K, Verfuerth S, et al. Adoptive cellular therapy for cytomegalovirus infection following allogeneic stem cell transplantation using virus-specific T cells. Blood Cells Mol Dis. 2008;40:63-67.
21. Meij P, Zandvliet ML, Van der Heiden PLJ, et al. Generation and administration of CMV pp65-specific donor T-cell lines for treatment of CMV reactivation after allogeneic stem cell transplantation. EBMT (Abstract) O-292-33rd Annual Meeting of the European Group for Blood and Marrow Transplantation, Lyon, France. 2007.
22. Micklethwaite K, Hansen A, Foster A, et al. Ex vivo expansion and prophylactic infusion of CMV-pp65 peptide-specific cytotoxic T-lymphocytes following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2007;13:707-714.
23. Micklethwaite KP, Clancy L, Sandher U, et al. Prophylactic infusion of cytomegalovirus specific cytotoxic T-lymphocytes stimulated with Ad5f35pp65 gene modified dendritic cells following allogeneic haemopoietic stem cell transplantation. Blood. 2008;112:3974-3981.
24. Holtappels R, Bohm V, Podlech J, et al. CD8 T-cell-based immunotherapy of cytomegalovirus infection: "proof of concept" provided by the murine model. Med Microbiol Immunol. 2008;197:125-134.
25. Tan R, Xu X, Ogg GS, et al. Rapid death of adoptively transferred T cells in acquired immunodefficiency syndrome. Blood. 1999;93:1506-1510.
26. + T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci USA. 2002;99:16168-16173.
27. + T cells. J Clin Invest. 2005;115:1616-1626.
28. Oved K, Ziv O, Jacob-Hirsch J, et al. A novel postpriming regulatory check point of effector/memory T cells dictated through antigen density threshold-dependent anergy. J Immunol. 2007;178:2307-2317.
29. Anderton SM, Radu CG, Lowrey PA, et al. Negative selection during the peripheral immune response to antigen. J Exp Med. 2001;193:1-11.
30. Alexander-Miller MA, Derby MA, Sarin A, et al. Supraoptimal peptide-major histocompatibility complex causes a decrease in bc1-2 levels and allows tumor necrosis factor alpha receptor II-mediated apoptosis of cytotoxic T lymphocytes. J Exp Med. 1998;188:1391-1399.
31. + CTL. Eur J Immunol. 2001;31:2951-2959.
32. + T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest. 2008;118:294-305.
33. Lohning M, Hegazy AN, Pinschewer DD, et al. Long-lived virus-reactive memory T cells generated from purified cytokine-secreting T helper type 1 and type 2 effectors. J Exp Med. 2008;205:53-61.
34. + T cells. Nature. 1999;401:76-79.
35. Slifka MK, Whitton JL. Antigen-specific regulation of T cellmediated cytokine production. Immunity. 2000;12:451-457.
36. + T cells is antigen independent. J Immunol. 2000;165:5387-5391.
37. Bissinger AL, Rauser G, Hebart H, et al. Isolation and expansion of human cytomegalovirus-specific cytotoxic T lymphocytes using interferon-gamma secretion assay. Exp Hematol. 2002;30:1178-1184.
38. + T-cell lines for adoptive transfer into recipients of allogeneic stem cell transplants. Blood. 2004;103:3565-3572.
39. Feuchtinger T, Matthes-Martin S, Richard C, et al. Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation. Br J Haematol. 2006;134:64-76.
40. Chatziandreou I, Gilmour KC, McNicol AM, et al. Capture and generation of adenovirus specific T cells for adoptive immunotherapy. Br J Haematol. 2007;136:117-126.
41. Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006;314:126-129.
42. Heemskerk MH, Hoogeboom M, Hagedoorn R, et al. Reprogramming of virus-specific T cells into leukemia-reactive T cells using T cell receptor gene transfer. J Exp Med. 2004;199:885-894.
43. Altman JD, Moss PA, Goulder PJ, et al. Phenotypic analysis of antigen-specific T lymphocytes. Science. 1996;274:94-96.
44. Seder RA, Darrah PA, Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol. 2008;8:247-258.
45. + T cells initiate IFN-gamma synthesis increases markedly over the course of infection and correlates with immunodominance. J Immunol. 2004;173:456-462.
46. Valitutti S, Muller S, Dessing M, et al. Different responses are elicited in cytotoxic T lymphocytes by different levels of T cell receptor occupancy. J Exp Med. 1996;183:1917-1921.
47. + T cell effector activity is dictated by cognate peptide concentration. J Immunol. 2004;172:6407-6417.
48. Liu H, Rhodes M, Wiest DL, et al. On the dynamics of TCR: CD3 complex cell surface expression and downmodulation. Immunity. 2000;13:665-675.
49. von Essen M, Bonefeld CM, Siersma V, et al. Constitutive and ligand-induced TCR degradation. J Immunol. 2004;173: 384-393.
50. Sallusto F, Kremmer E, Palermo B, et al. Switch in chemokine receptor expression upon TCR stimulation reveals novel homing potential for recently activated T cells. Eur J Immunol. 1999;29:2037-2045.
51. + T cells upon antigenic stimulation. Int Immunol. 2005;17:713-719.